Campus Biotech start-up Neurosoft Bioelectronics is developing flexible, biocompatible 5x5 cm brain implants, primarily for epilepsy patients for whom medication is not effective. These implants, fitted with 64 electrodes, enable neurosurgeons to differentiate between healthy brain tissue and epileptic areas, thereby reducing the risks during surgery.
The start-up completed a European clinical trial in February 2025 with 12 patients. Since its creation in 2020, it has raised 11 million Swiss francs and plans to raise further funds to develop solutions for other pathologies, including severe tinnitus. It is looking to use implanted electrodes to modulate brain activity and thus treat conditions such as head trauma, deafness and spinal cord injury.
Neurosoft Bioelectronics produces its implants in-house and collaborates with academic institutions and hospitals to accelerate clinical development.
Read the full Bilan article here.
Photo: © Jimmy Ravier/Neurosoft
News